William Reardon - Tekla World Independent Trustee
| THW Fund | USD 13.01 0.02 0.15% |
Mr. William S. Reardon, CPA serves as an Independent Trustee of the Tekla World Healthcare Fund. Mr. Reardons personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP, with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. Until 2002, Mr. Reardon was a business assurance partner in PwCs Boston office and leader of the Life Sciences Industry Practice for New England and the Eastern U.S., working closely with many of the Firms public clients in SECregistered equity, convertible and RD limited partnership offerings and many initial public offerings. He serves on the Valuation and Audit Committees of each Fund. From 19982000 he served on the Board of the Emerging Companies Section of the Biotechnology Industry Organization and from 2000 to 2002 he served on the Board of Directors of the Massachusetts Biotechnology Council . During his professional career, he was a frequent speaker at BIO conferences and MBC Industry meetings on issues affecting biotechnology companies. He currently also serves as a board member and audit committee chair of two developmentstage public companies, Synta Pharmaceuticals and Idera Pharmaceuticals
| Age | 74 |
| Tenure | 9 years |
| Professional Marks | CPA |
| Phone | 617 772 8500 |
| Web | https://www.teklacap.com/thw.html |
Tekla World Management Performance (%)
Similar Money Managers
| Showing other executives | One Year Return | ||
| Susan Sutherland | Eaton Vance Tax | 64 | |
| Harriett Taggart | Eaton Vance Tax | 71 | |
| Lucinda Stebbins | Tekla Life Sciences | 73 | |
| Charles Bardelis | John Hancock Financial | 79 | |
| Theron Hoffman | John Hancock Financial | 72 | |
| Lucinda Stebbins | Tekla Healthcare Investors | 73 | |
| Laurie Lodolo | Flaherty and Crumrine | 56 | |
| Deborah Jackson | John Hancock Financial | 68 | |
| Peter Branner | Tekla Life Sciences | N/A | |
| Thomas Kent | Tekla Healthcare Investors | 67 | |
| Michael Holland | Reaves Utility If | 75 | |
| Lauren CFA | Royce Value Closed | N/A | |
| Gregory Russo | John Hancock Financial | 71 | |
| Frank Gentile | Tekla Healthcare Investors | 62 | |
| Christopher Flynn | Royce Value Closed | N/A | |
| Dr MS | Tekla Healthcare Investors | 71 | |
| Laura Woodward | Tekla Healthcare Investors | 51 | |
| George Gorman | Eaton Vance Tax | 69 | |
| Christopher MBA | Tekla Healthcare Investors | N/A | |
| James Kirchner | Eaton Vance Tax | 54 | |
| Elizabeth Nabel | Tekla Healthcare Investors | 67 | |
Tekla World Healthcare Leadership Team
Elected by the shareholders, the Tekla World's board of directors comprises two types of representatives: Tekla World inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla World's management team and ensure that shareholders' interests are well served. Tekla World's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla World's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Oleg Pohotsky, Independent Chairman of Board of Trustees | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, President Trustee | ||
| Rakesh Jain, Independent Trustee |
Tekla Fund Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right fund is not an easy task. Is Tekla World a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Shares Outstanding | 37.49 M | ||||
| Shares Owned By Institutions | 11.77 % | ||||
| Number Of Shares Shorted | 157.29 K | ||||
| Price To Earning | 12.08 X | ||||
| Short Ratio | 1.43 X | ||||
| Earnings Per Share | 1.16 X | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 600.4 M | ||||
| Annual Yield | 0.01 % | ||||
| Year To Date Return | 8.76 % |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tekla World Healthcare. Also, note that the market value of any fund could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Tekla World Healthcare information on this page should be used as a complementary analysis to other Tekla World's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.